↓ Skip to main content

American Association for Cancer Research

Article Metrics

Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma

Overview of attention for article published in Molecular Cancer Therapeutics, July 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
4 tweeters
patent
3 patents

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
27 Mendeley
Title
Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Published in
Molecular Cancer Therapeutics, July 2019
DOI 10.1158/1535-7163.mct-18-1216
Pubmed ID
Authors

Tatsushi Kodama, Yu Kochi, Waka Nakai, Hideaki Mizuno, Takeshi Baba, Kiyoshi Habu, Noriaki Sawada, Hiroyuki Tsunoda, Takahiro Shima, Kohta Miyawaki, Yoshikane Kikushige, Yasuo Mori, Toshihiro Miyamoto, Takahiro Maeda, Koichi Akashi

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 22%
Other 5 19%
Researcher 5 19%
Professor > Associate Professor 3 11%
Student > Bachelor 2 7%
Other 4 15%
Unknown 2 7%
Readers by discipline Count As %
Medicine and Dentistry 12 44%
Agricultural and Biological Sciences 3 11%
Biochemistry, Genetics and Molecular Biology 3 11%
Immunology and Microbiology 3 11%
Arts and Humanities 1 4%
Other 2 7%
Unknown 3 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2021.
All research outputs
#2,845,283
of 17,011,884 outputs
Outputs from Molecular Cancer Therapeutics
#514
of 3,184 outputs
Outputs of similar age
#62,016
of 268,068 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#6
of 35 outputs
Altmetric has tracked 17,011,884 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,068 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.